EraCal Therapeutics AG
We develop the next generation anti-obesity drug
Excess weight and obesity are among the most widespread health risks globally. EraCal fights it: the University of Zurich and Harvard University spin-off, founded in 2018, develops novel appetite suppressants to combat obesity. Reducing appetite facilitates blood sugar and lipid control, reduces body weight and liver fat content, and facilitates healthy aging. The front-running program Era-379 was outlicensed to Novo Nordisk, the world-leader in anti-obesity pharmacotherapy, in January 2024 for €235M plus royalties.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
Last Tweets
No Jobs
No videos and documents
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Venture Leaders Life Sciences
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
EraCal Therapeutics AG
We develop the next generation anti-obesity drug
Website:
www.eracal.ch/
Headquarter:
Basel
Foundation Date:
October 2018
Technology:
- Biotech
Sectors:
- Biotech
- Drug development platforms
- Drug discovery
- Research and development
- Small molecule drugs
Support received
